Equillium(EQ) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights $33.3 million cash balance at the end of Q2 2024, representing a $1.0 million increase from the end of Q1 2024 Triggered Ono option exercise period to acquire Equillium's rights to itolizumab, decision expected before the end of October 2024 Announced positive interim analysis of Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease subjects Announced positive topline d ...